Radiation Pneumonitis Treatment Market Size & Share, by Treatment Type (Corticosteroids, Decongestants, Cough Suppressants, Bronchodilators, Oxygen Therapy); End user - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Radiation Pneumonitis Treatment Industry - Regional Synopsis

North America Market Statistics   

The radiation pneumonitis treatment market in North America is expected to dominate during the forecast timeline, i.e., from 2025 to 2037, with a notable share of 37.3%. The use of customized medicine in cancer therapies, especially radiation therapy, has increased in the region. Clinicians now customize treatment plans based on patient features, such as genetic predispositions for radiation-induced lung injury, owing to the growing advancements in genomic profiling and biomarker discovery scope within the region.

In the U.S. radiation pneumonitis treatment market is likely to unveil lucrative growth opportunities owing to the legislations facilitating the expansion of investigational studies, accompanied by supportive reimbursement policies. For instance, in March 2025, supported by representatives, the Radiation Oncology Case Rate (ROCR) Value-Based Payment Program Act of 2025 would preserve access to high-quality cancer care, improve patient outcomes, and save money for Medicare. The ROCR Act offers a patient-centered approach to updating Medicare's radiation therapy reimbursement program. Through the transition from the existing quantity-based, per-treatment system to patient-focused, episode-based payments, ROCR places more emphasis on the value and quality of care than the frequency of treatment appointments.

The Canada radiation pneumonitis treatment market is exponentially increasing its footprint, owing to the awareness and open-ended discussions between scholars, researchers, and eminent companies fostering the same goal. For instance, in April 2024, at the Annual RTi3 Conference in Canada, radiation therapists came together to discuss the most recent developments and innovations in radiation therapy which centered on disease sites, planning for operations and treatments, and patient care and experience. This conference offered an opportunity for networking and involvement in state-of-the-art technology to bring improvements in healthcare.

Asia Pacific Market Analysis

The radiation pneumonitis treatment market in Asia Pacific is likely to witness the fastest growth during the stipulated timeframe. The growth is attributed to the efforts of researchers who are investigating the synergistic effects of combination therapies with immunotherapy, targeted therapies, and supportive interventions. Furthermore, the advancements in antioxidants or anti-inflammatory drugs to increase efficacy while reducing side effects are gaining traction. In addition to improving treatment results, combination techniques can lower incidence and severity rates, which will lead to a larger market share.

In India radiation pneumonitis treatment market is likely to witness robust growth owing to the expanding healthcare facilities. For instance, in October 2024, in a pioneering move that sets a new benchmark in cancer treatment, Aster DM Healthcare became the first healthcare facility in the country to implement Intra-Operative Electron Radiation Therapy (IOeRT), marking a seminal shift in cancer care. The new state-of-the-art medical facility was made available at the Aster International Institute of Oncology (AIIO), Aster Whitefield Hospital, Bengaluru, and represents a significant leap forward in the hospital’s commitment to providing the highest quality treatment options for cancer patients.

The China radiation pneumonitis treatment market is likely to flourish at a fast pace during the stipulated timeline due to the focus on innovative and transformative radiation therapy. For instance, in June 2024, the Chinese National Medical Products Administration (NMPA) approved the registration dossier for the Accuray Precision Treatment Planning System (TPS). It is compatible with the CNNC-Accuray joint venture Tomo C radiation therapy system. This modality was a new way to deliver incredibly accurate and precise radiation treatments, which will ultimately increase the number of cancer patients in China who have access to care.